Portable Gene Therapy Platform for Point-of-Care Cell Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in achieving safe and efficient gene transfer to target cells while minimizing gene transfer to non-target cells, requiring complex centralized facilities and adhering to stringent regulatory guidelines, which limits accessibility and increases costs.
Innovation Solution
A portable and point-of-care device for ex vivo isolation, production, and formulation of gene-modified cells using a closed-loop sterile software-enabled system that performs genetic modifications with minimal user input, enabling efficient isolation, modification, and formulation of target cells within 30 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complex centralized facilities are used for ex vivo gene therapy manufacturing, then safety and efficacy standards are maintained, but accessibility and cost are worsened
Solution Approach 1:
The patent segments the centralized manufacturing process into modular functional units (cell separation module, transfection module, culture module, formulation module) that can be distributed across multiple locations. Each module performs a specific function and can be operated independently, allowing gene therapy production to occur in decentralized settings while maintaining quality standards through standardized protocols.
Solution Approach 2:
The system incorporates automated control and monitoring that enables the manufacturing process to self-regulate critical parameters (temperature, pH, cell density, sterility). This automation reduces dependency on highly specialized personnel and complex facility infrastructure, making the process accessible to smaller or less resource-intensive centers while maintaining GMP compliance.
2Reliability
If complex centralized facilities are used for ex vivo gene therapy manufacturing, then safety and efficacy standards are maintained, but costs are increased
Solution Approach 1:
By dividing the manufacturing process into discrete modular units, the system eliminates the need for expensive centralized facility infrastructure. Each module can be housed in simpler, less costly environments, and the modular architecture allows for right-sizing capacity to match demand, reducing overhead costs while maintaining quality through standardized operational protocols.
Solution Approach 2:
The system employs automated real-time monitoring and adjustment of critical process parameters (temperature, pH, dissolved oxygen, cell density) to ensure consistent product quality. This parameter control through automation reduces the need for expensive manual quality control procedures and expensive facility infrastructure, achieving cost reduction while maintaining safety and efficacy standards.
3Manufacturing precision
If traditional gene therapy processes are used, then thorough cell processing is achieved, but time required is excessive
Solution Approach 1:
The patent implements continuous processing where cell separation, transfection, and culture operations occur in an uninterrupted sequence through the modular system. Cells flow continuously from one module to the next without batch processing interruptions, maintaining thorough processing quality while significantly reducing total manufacturing time from weeks to days or hours.
Solution Approach 2:
The system performs preliminary cell separation and preparation in dedicated modules before transfection, pre-configuring the cell population for optimal genetic modification. This preliminary action ensures thorough processing of each cell subpopulation while reducing overall time by avoiding sequential batch processing and enabling parallel operations across modules.
4Adaptability or versatility
If manual user input is required for gene modification processes, then flexibility is maintained, but automation and efficiency are reduced
Solution Approach 1:
Each modular unit is designed with universal interfaces and standardized protocols that can handle different cell types and gene therapy protocols. The modules perform multiple functions (separation, concentration, transfection) and can be configured for various therapeutic applications, providing both automation efficiency and adaptability to different clinical needs through reconfigurable standardized components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces the risk of sample contamination, decreases dependency on immovable medical facilities, and makes gene therapy more widely available by simplifying the process and reducing the time required for gene modification, while maintaining safety and efficacy standards.
Implementation Method 1
various non-target sample components may be removed from the sample. For example, one or both of red blood cells (RBCs) or platelets (thrombocytes) may be separated from the target cells and removed from the sample
Implementation Method 2
a particular 'incubation' environment may be maintained within the first treatment chamber in order to facilitate association of labeling agent(s) with the target cells
Data Source
AI summary
A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.